Header Logo

Connection

HUSSEIN TAWBI to Treatment Outcome

Back to Details
This is a "connection" page, showing publications HUSSEIN TAWBI has written about Treatment Outcome.
HUSSEIN TAWBI
Connection Strength
0.320
Treatment Outcome
  1. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020 03 15; 26(6):1258-1266.
    View in: PubMed
    Score: 0.041
  2. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 11; 18(11):1493-1501.
    View in: PubMed
    Score: 0.035
  3. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017 09 19; 5(1):74.
    View in: PubMed
    Score: 0.035
  4. Immunotherapeutic approaches to sarcoma. Curr Treat Options Oncol. 2015 Jun; 16(6):26.
    View in: PubMed
    Score: 0.030
  5. Combination therapies for treating metastatic melanoma. Clin Adv Hematol Oncol. 2015 Apr; 13(4):211-4.
    View in: PubMed
    Score: 0.029
  6. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.
    View in: PubMed
    Score: 0.013
  7. Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2021 10; 88(4):643-654.
    View in: PubMed
    Score: 0.011
  8. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.011
  9. A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng. 2021 04; 5(4):297-308.
    View in: PubMed
    Score: 0.011
  10. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 10; 26(10):1557-1563.
    View in: PubMed
    Score: 0.011
  11. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol. 2019 12; 84(6):1289-1301.
    View in: PubMed
    Score: 0.010
  12. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. 2019 Dec 01; 125(23):4193-4202.
    View in: PubMed
    Score: 0.010
  13. NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. Cancer. 2018 11 15; 124(22):4332-4341.
    View in: PubMed
    Score: 0.009
  14. Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila). 2018 07; 11(7):429-438.
    View in: PubMed
    Score: 0.009
  15. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.009
  16. A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res. 2018 01 01; 24(1):22-32.
    View in: PubMed
    Score: 0.009
  17. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Nov; 78(5):921-927.
    View in: PubMed
    Score: 0.008
  18. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016 Mar 15; 122(6):868-74.
    View in: PubMed
    Score: 0.008
  19. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res. 2015 Feb 01; 21(3):585-93.
    View in: PubMed
    Score: 0.007
  20. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8? T cells induced by melanoma vaccines. Cancer Res. 2014 Feb 15; 74(4):1045-55.
    View in: PubMed
    Score: 0.007
  21. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007 Nov; 12(11):1344-50.
    View in: PubMed
    Score: 0.004
  22. Calcitonin in the treatment of transient osteoporosis of the hip. Semin Arthritis Rheum. 2003 Jun; 32(6):388-97.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.